2019
Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder
Verplaetse TL, Ralevski E, Roberts W, Gueorguieva R, McKee SA, Petrakis IL. Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder. Alcohol Clinical And Experimental Research 2019, 43: 741-746. PMID: 30698839, PMCID: PMC6443463, DOI: 10.1111/acer.13969.Peer-Reviewed Original ResearchConceptsAlcohol use disorderPosttraumatic stress disorderPlacebo-treated individualsTotal CAPS scoresClinical trialsCAPS scoresPrazosin treatmentComorbid populationPTSD symptomsUse disordersClinician-Administered PTSD Scale scoresDouble-blind clinical trialStress disorderComorbid alcohol use disorderPrazosin-treated groupSymptoms of PTSDRecent clinical trialsComorbid alcohol dependenceCourse of treatmentΑ1-adrenergic antagonistPosttraumatic stress disorder (PTSD) symptomsOngoing symptomsSleep disturbancesMedication effectsNoradrenergic system
2018
Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking
Roberts W, Ralevski E, Verplaetse TL, McKee SA, Petrakis IL. Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. Journal Of Substance Use And Addiction Treatment 2018, 94: 91-96. PMID: 30243424, PMCID: PMC6154389, DOI: 10.1016/j.jsat.2018.08.015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcohol DrinkingAlcoholismDouble-Blind MethodFemaleHumansMaleMecamylamineMiddle AgedNicotinic AntagonistsTobacco SmokingTreatment OutcomeConceptsAlcohol use disorderClinical trialsSmoking outcomesNicotinic acetylcholine receptor antagonistAlcohol useHigh-dependence smokersEffects of mecamylamineSubgroups of smokersAcetylcholine receptor antagonistHigh tobacco dependencePlacebo groupMedication conditionReceptor antagonistMedication effectsTobacco dependenceTobacco useTreatment respondersMecamylamineSmokingTreatment phaseUse disordersAlcohol dependenceSmokersTrialsSignificant differencesA preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco‐deprived and ‐satiated smokers
Roberts W, Verplaetse TL, Moore KE, Oberleitner LM, McKee SA. A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco‐deprived and ‐satiated smokers. Human Psychopharmacology Clinical And Experimental 2018, 33: e2660. PMID: 29878501, PMCID: PMC5995328, DOI: 10.1002/hup.2660.Peer-Reviewed Original ResearchConceptsContinuous performance taskInhibitory controlCognitive functioningPerformance taskTobacco withdrawalEffects of doxazosinSustained attentionCognitive performanceWithdrawal symptomsCognitive AssessmentSmoking outcomesMost measuresSelf-reported withdrawal symptomsReaction timeTaskParticipantsFunctioningPredrug levelsΑ1 antagonistTitration periodGreater improvementDoxazosinSmokingSymptomsPreliminary investigation